Drug Type | Administration Route | Pharmacokinetic Parameter | Clearance Pathway | Drug Interaction | Therapeutic Window | References |
---|---|---|---|---|---|---|
Doxorubicin | Intravenous | Area Under Curve (AUC) | Hepatic Metabolism | P-glycoprotein | Narrow | [201] |
Paclitaxel | Intravenous | Half-life | Renal Excretion | Cytochrome P450 | Wide | [57] |
Cisplatin | Intraperitoneal | Volume of Distribution | Renal Excretion | None | Narrow | |
Irinotecan | Oral | Bioavailability | Hepatic Metabolism | UDP-glucuronosyltransferase | Wide | [202] |
Methotrexate | Intrathecal | Cerebrospinal Fluid Concentration | Renal Excretion | None | Narrow | [99] |
Gemcitabine | Intravenous | Clearance Rate | Renal Excretion | Deoxycytidine Kinase | Wide | [203] |
Etoposide | Intravenous | Distribution Half-life | Hepatic Metabolism | Cytochrome P450 | Wide | [204] |
Oxaliplatin | Intravenous | Total Clearance | Renal Excretion | None | Narrow | [205] |
Topotecan | Oral | Bioavailability | Hepatic Metabolism | Cytochrome P450 | Narrow | [206] |
Docetaxel | Intravenous | Protein Binding | Hepatic Metabolism | P-glycoprotein | Wide | [207] |
Methotrexate | Intravenous | Clearance | Renal Excretion | None | Narrow | [208] |
Trastuzumab | Intravenous | Volume of Distribution | Proteolysis | None | Wide | [189] |
Docetaxel | Intravenous | Protein Binding | Hepatic Metabolism | P-glycoprotein | Wide | [117] |
Bleomycin | Intravenous | Half-life | Renal Excretion | None | Narrow | [209] |
Vinorelbine | Oral | Bioavailability | Hepatic Metabolism | P-glycoprotein | Wide | [210] |
Daunorubicin | Intravenous | AUC | Hepatic Metabolism | P-glycoprotein | Narrow | [211] |
Cisplatin | Intravenous | Half-life | Renal Excretion | None | Narrow | [212] |
Pemetrexed | Intravenous | Protein Binding | Renal Excretion | None | Narrow | [213] |
Everolimus | Oral | Bioavailability | Hepatic Metabolism | Cytochrome P450 | Wide | [214] |
Tamoxifen | Oral | Clearance | Hepatic Metabolism | None | Wide | [215] |